CD3/CD123 bispecific antibody (Baylor Scott & White Research Institute)

N/A

Report date: 2026/03/19 16:53:42

Base Information

Drug NameCD3/CD123 bispecific antibody (Baylor Scott & White Research Institute)
Drug Alias Nameanti-CD3/anti-CD123 bispecific T-cell engager (Baylor Scott & White Research Institute)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionInterleukin-3 receptor subunit alpha modulatorsT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3Interleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, Hairy Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBaylor Scott & White Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesBaylor Scott & White Research Institute
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, Hairy Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A